|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
7 JUNE 2010
|
| |
|
This expert interview with Gini Fleming, MD, from the University of Chicago Medical Center in Chicago, Illinois, and Mary Cianfrocca, DO, from Northwestern University in Chicago, Illinois, discusses the topic gynecologic malignancies, focusing on the following data releases:
#5003: A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA)
#5004: A gene expression profile of BRCAness that correlates with responsiveness to platinum and PARP inhibitors
#LBA5008: Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report
#LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study
|
| |
|
View an expert interview and opinion with Gini Fleming, MD, and Mary Cianfrocca, DO 
Click here to complete the post-test online |
|
|
|
|
|
|
